Breakthrough trial tests Next-Gen drug to stop bleeds in hemophilia patients
NCT ID NCT07416526
Summary
This study aims to see if a new preventive drug called NXT007 works better and is safer than the current standard Factor VIII treatment for people with moderate to severe Hemophilia A. It will involve about 126 participants aged 12 and older who are already using Factor VIII to prevent bleeds. The main goal is to see which treatment leads to fewer bleeding episodes that need treatment over the study period.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMOPHILIA A are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Nara Medical University Hospital
RECRUITINGKashihara-shi, Nara, 634-8522, Japan
-
Tokyo Medical University Hospital
RECRUITINGShinjuku-Ku, Tokyo, 160-0023, Japan
Conditions
Explore the condition pages connected to this study.